PriceTargets.com logo

Provention Bio - PRVB Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$24.98 As of 04/27/2023 09:00 PM ET
▲ +0.75 (3.10%)
Get New Provention Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRVB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRVB

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Provention Bio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $24.98.

This chart shows the closing price for PRVB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Provention Bio. This rating has held steady since March 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/15/2023HC WainwrightDowngradeBuy ➝ Neutral$16.00 ➝ $25.00
3/14/2023Sumitomo Mitsui Financial GroupReiterated RatingOutperform ➝ Neutral$15.00 ➝ $25.00
3/14/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$25.00
3/13/2023Chardan CapitalLower TargetBuy$30.00 ➝ $25.00
3/13/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral
2/15/2023HC WainwrightLower TargetBuy$18.00 ➝ $16.00
11/21/2022Leerink PartnersBoost TargetOutperform$16.00 ➝ $19.00
11/18/2022Chardan CapitalBoost TargetBuy$24.00 ➝ $30.00
11/18/2022OppenheimerBoost TargetOutperform$14.00 ➝ $18.00
11/18/2022Jefferies Financial GroupBoost TargetBuy$18.00 ➝ $22.00
11/4/2022Chardan CapitalBoost TargetBuy$21.00 ➝ $24.00
10/6/2022Jefferies Financial GroupBoost TargetBuy$10.00 ➝ $15.00
9/20/2022Jefferies Financial GroupInitiated CoverageBuy$10.00
8/5/2022Chardan CapitalLower TargetBuy$22.50 ➝ $21.00
7/11/2022HC WainwrightLower TargetBuy$25.00 ➝ $18.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
1/31/2022HC WainwrightReiterated RatingBuy$25.00
11/23/2021Sumitomo Mitsui Financial GroupUpgradeNeutral ➝ Outperform
11/23/2021UBS GroupUpgradeNeutral ➝ Outperform
9/20/2021Leerink PartnersReiterated RatingBuy$16.00
9/14/2021HC WainwrightReiterated RatingBuy$25.00
8/6/2021HC WainwrightLower TargetBuy$27.00 ➝ $25.00
8/6/2021OppenheimerLower TargetOutperform$18.00 ➝ $16.00
7/11/2021Royal Bank of CanadaReiterated RatingHold$8.00
7/7/2021HC WainwrightReiterated RatingBuy$27.00
7/1/2021Chardan CapitalReiterated RatingBuy
5/31/2021Leerink PartnersReiterated RatingBuy$16.00
5/28/2021Chardan CapitalLower TargetBuy$35.00 ➝ $22.50
5/28/2021OppenheimerReiterated RatingBuy$18.00
5/7/2021Cantor FitzgeraldLower TargetOverweight$25.00 ➝ $19.00
5/7/2021OppenheimerReiterated RatingBuy$18.00
4/28/2021HC WainwrightReiterated RatingBuy$27.00
4/19/2021HC WainwrightReiterated RatingBuy$34.00 ➝ $27.00
4/15/2021Royal Bank of CanadaReiterated RatingOutperform ➝ Sector Perform$25.00 ➝ $10.00
4/12/2021Chardan CapitalLower TargetBuy$35.00 ➝ $22.50
4/12/2021HC WainwrightLower TargetBuy$34.00 ➝ $27.00
4/9/2021Leerink PartnersLower TargetOutperform$26.00 ➝ $16.00
4/9/2021OppenheimerReiterated RatingBuy$18.00
4/9/2021Cantor FitzgeraldLower TargetOverweight$27.00 ➝ $25.00
4/9/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$27.00 ➝ $25.00
2/25/2021Chardan CapitalLower TargetBuy$40.00 ➝ $35.00
2/22/2021HC WainwrightBoost TargetBuy$26.00 ➝ $34.00
1/4/2021Chardan CapitalBoost TargetPositive ➝ Buy$35.00 ➝ $40.00
11/3/2020Chardan CapitalReiterated RatingBuy$35.00
10/2/2020HC WainwrightReiterated RatingBuy$26.00
9/23/2020OppenheimerReiterated RatingBuy$29.00
8/18/2020Royal Bank of CanadaReiterated RatingBuy
7/14/2020OppenheimerInitiated CoverageBuy$29.00
7/2/2020HC WainwrightReiterated RatingBuy$26.00
6/16/2020Chardan CapitalBoost TargetBuy$30.00 ➝ $40.00
6/16/2020HC WainwrightBoost TargetBuy$20.00 ➝ $26.00
6/15/2020OppenheimerInitiated CoverageBuy$29.00
6/4/2020Royal Bank of CanadaInitiated CoverageOutperform$25.00
6/3/2020OppenheimerInitiated CoverageOutperform$29.00
5/8/2020HC WainwrightReiterated RatingBuy$20.00
4/17/2020HC WainwrightReiterated RatingBuy$20.00
4/1/2020Chardan CapitalBoost TargetBuy$18.50 ➝ $30.00
3/18/2020HC WainwrightReiterated RatingBuy
1/24/2020Cantor FitzgeraldInitiated CoverageOverweight$25.00
1/2/2020Leerink PartnersReiterated RatingOutperform
12/30/2019HC WainwrightReiterated RatingBuy$20.00
(Data available from 12/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Provention Bio logo
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.
Read More

Today's Range

Now: $24.98
Low: $24.98
High: $25.00

50 Day Range

MA: $24.58
Low: $23.74
High: $24.98

52 Week Range

Now: $24.98
Low: $3.18
High: $25.00

Volume

9,124,100 shs

Average Volume

2,277,701 shs

Market Capitalization

$2.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Provention Bio?

The following Wall Street sell-side analysts have issued stock ratings on Provention Bio in the last twelve months:
View the latest analyst ratings for PRVB.

What is the current price target for Provention Bio?

0 Wall Street analysts have set twelve-month price targets for Provention Bio in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Provention Bio in the next year.
View the latest price targets for PRVB.

What is the current consensus analyst rating for Provention Bio?

Provention Bio currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PRVB.

What other companies compete with Provention Bio?

Other companies that are similar to Provention Bio include Intra-Cellular Therapies, Roivant Sciences, Ascendis Pharma A/S, Jazz Pharmaceuticals and Madrigal Pharmaceuticals. Learn More about companies similar to Provention Bio.

How do I contact Provention Bio's investor relations team?

Provention Bio's physical mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company's listed phone number is (908) 428-9136 and its investor relations email address is [email protected]. The official website for Provention Bio is www.proventionbio.com. Learn More about contacing Provention Bio investor relations.